Tiziana life sciences announces live bloomberg tv interview of renowned scientist dr. howard l. weiner to discuss fda ind clearance for intranasal foralumab in alzheimer's disease

New york, aug. 17, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa ) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that dr. howard l. weiner, a thought leader in the field of neurology and immunology, was featured in an exclusive live interview on bloomberg to discuss the company's latest announcement on its advancement of the novel foralumab program in alzheimer's disease following recent u.s. food and drug administration (fda) investigational new drug (ind) clearance. foralumab is the only fully human anti-cd3 monoclonal antibody in clinical development.
TLSA Ratings Summary
TLSA Quant Ranking